Related Experiment Video
Updated: Jun 4, 2026

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes
Published on: October 10, 2025
Is an emerging pharmacotherapeutic era for rare mitochondrial diseases here?
Jirair K Bedoyan1, Jerry Vockley1
1Division of Genetic and Genomic Medicine, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
Abstract:
After decades without approved pharmacotherapies, mitochondrial disease care is shifting. Two FDA approvals emerged in 1 year, elamipretide (Forzinity) for Barth syndrome and deoxynucleoside therapy (Kygevvi) for TK2 deficiency, with another under review. Zink et al.1 suggest sildenafil (Viagra) could treat Leigh syndrome, highlighting drug repurposing for severe pediatric mitochondrial disease.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Pharmacogenomics: Identification of New Drug Targets
Animal Mitochondrial Genetics
Mitochondrial Precursor Proteins
Most of the mitochondrial precursors...
Mitochondrial Membranes

